Connecticut's Biotech Sector Unites Against Federal Headwinds

NEW HAVEN, CT – January 27, 2026 – Top state officials, academic leaders, and life sciences executives convened this week to forge a united strategy for Connecticut’s thriving biotechnology sector, drawing battle lines against what they termed an “assault on science” from shifting federal priorities. The third annual BioCT Legislative Breakfast, held virtually due to a winter storm, transformed into a strategic summit focused on protecting the state's innovation economy ahead of the 2026 legislative session.

The event, co-hosted by BioCT and Alexion, AstraZeneca Rare Disease, brought together key figures including Governor Ned Lamont and U.S. Senator Richard Blumenthal. They outlined a proactive, state-level response to federal funding uncertainties and regulatory challenges, emphasizing a commitment to not only defend but also expand Connecticut’s significant life sciences footprint, which contributes over $7 billion to the state GDP and supports more than 24,000 jobs.

“Thanks to strong leadership, Connecticut’s life sciences industry is thriving,” said Jodie Gillon, President and CEO of BioCT. “As we navigate ongoing changes and challenges from the federal government, it is essential to inform our legislative partners... to ensure Connecticut residents have access to testing and medicines.”

A State Braces Against Federal 'Assault'

The urgency of the discussion was underscored by Senator Richard Blumenthal, who delivered a stark warning about the current federal climate.

“We are in the midst of the greatest assault on science and research—scientific progress—since maybe the Middle Ages,” Senator Blumenthal stated during a panel on federal issues. He described a landscape where scientific fact is under fire and called for a robust, unified response. “The bottom line here is we need to fight back, and I view this gathering as a kind of call to action.”

This sentiment is rooted in concrete federal actions over the past year. In 2025, the scientific community nationwide was shaken as over 3,800 research grants from the National Institutes of Health (NIH) and National Science Foundation (NSF) were frozen or terminated, representing nearly $3 billion in unfunded projects. The administration’s fiscal year 2026 budget proposal sought to slash NIH funding by 40%. While the U.S. House recently passed a spending package that largely rejected these cuts and provided a modest increase for the NIH, the initial threat has left a lasting impact.

Nancy Brown, Dean of Yale School of Medicine, described the “sense of whiplash” from the funding uncertainty, noting the direct economic consequences for the state. Each dollar of federal research funding, she explained, generates approximately $2.50 in local economic activity, making federal disruptions a significant threat to Connecticut's growth.

Doubling Down on Homegrown Innovation

In response to federal volatility, Connecticut is doubling down on its own strategic investments. Governor Lamont highlighted the state’s commitment to fostering an environment where innovation can flourish, independent of Washington's whims.

“You’ve got to tell us where we can make a difference, where we are stifling innovation or getting in the way,” Governor Lamont urged the assembled leaders, reinforcing his administration’s collaborative stance.

This commitment is backed by substantial state funding. In September 2025, Governor Lamont designated New Haven as the state’s first “Innovation Cluster,” injecting $50.5 million into the city’s ecosystem. The investment is designed to supercharge the local life sciences hub through public infrastructure upgrades, the development of nearly 500,000 square feet of new lab and life sciences facilities, and dedicated programming support for BioCT.

Beyond traditional biotech, the state is making a bold play in next-generation technology. The QuantumCT initiative, a partnership between UConn, Yale, and the state, has been fueled by a $121 million state pledge to establish Connecticut as a national leader in quantum technologies. The initiative is currently a finalist for a coveted National Science Foundation Regional Innovation Engines grant, which could bring up to $160 million in additional federal funding in early 2026. These efforts are part of a broader strategy articulated by DECD Commissioner Daniel O’Keefe.

“Our strategy remains to double down on the sectors where we have a clear competitive advantage, and biotechnology is at the forefront,” said Commissioner O’Keefe. “Through investments in quantum, AI, and biotech, we are working to make sure Connecticut continues to lead.”

Policy, Patents, and a Sharpening Competitive Edge

While major investments make headlines, state leaders and industry advocates are also focused on the intricate policy levers that can make or break a competitive ecosystem. In 2025, lawmakers enacted a crucial enhancement to the R&D tax credit program. The change allows small, non-profitable biotech firms to exchange their unused tax credits for cash at a rate of 90%, up from 65%—a significant boost to free cash flow for reinvestment in research.

Despite these wins, the pressure to remain competitive is intense. Other biotech hubs like Boston are actively recruiting promising Connecticut startups with aggressive incentive packages. One New Haven-based AI-biotech CEO recently noted the attractive offers his growing company received to relocate, underscoring the need for Connecticut to act swiftly and decisively.

This is the challenge the Connecticut General Assembly’s Bioscience Caucus is prepared to meet. “We really want Connecticut to be a place not only where ideas and innovation happen, but where those innovations can really be incubated, commercialized, scaled, and delivered in a widespread way,” said Caucus Co-chair Senator Christine Cohen.

Her colleague, Senator Tony Hwang, emphasized the importance of stability and accessibility. “This constant dialogue is critical for us as legislators,” he said. “A sense of stability and vision is critical to recruit, retain, and grow our bioscience businesses.”

Looking ahead to the 2026 session, which begins February 4, BioCT will advocate for its new Legislative Agenda, which includes calls for further enhancements to the R&D tax credit and other incentives designed to keep the state at the forefront of an intensely competitive global industry.

As Arvinas CEO John Houston noted, the state possesses world-class universities generating powerful ideas. The challenge, he argued, is to ensure those ideas grow into companies that stay in Connecticut. “I think we have incredibly innovative ideas,” Houston said. “We have got superb universities that generate great ideas and those universities want to spin companies off into Connecticut.”

This statewide, multi-faceted effort—combining major capital investments with granular policy adjustments and a unified political voice—represents Connecticut’s comprehensive strategy to secure its place as a powerhouse in the past, present, and future of life sciences. As Bexorg CEO Zvonimir Vrselja remarked, the state has the potential to be a “launchpad for national impact and for global impact” by playing to its unique strengths.